AstriVax Therapeutics
0787.990.881 · rovalta.com · 25/09/2026
AstriVax Therapeutics
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOAstriVax Therapeutics is a Public limited company incorporated in 2022. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 17,1 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0787.990.881
- Incorporation
- 04/07/2022
- Legal form
- Public limited company
- Registered office
- Gaston Geenslaan 3 box 4
3001 Leuven · FlandreSee on map - Contributed capital
- 15 770 455,92 €
- Latest accounts
- 31/12/2025
- Average workforce
- 17,1 ETP
Joint committees (2)
- 20700
- 207000
Financials
Source · NBB, 5 filingsTrend over 3 financial years
| 2025 | 2024 | 2023 | |||
|---|---|---|---|---|---|
| Income statement | |||||
| Gross margin | – | – | -5,3 M € | ||
| EBITDA | 240 k € | +103% | -8,6 M € | -33.7% | -6,4 M € |
| Operating result | -8,2 M € | +9.8% | -9,1 M € | -28.9% | -7 M € |
| Net result | -7,7 M € | +6.6% | -8,2 M € | -21.6% | -6,7 M € |
| Balance sheet | |||||
| Equity | 10,7 M € | -41.7% | 18,3 M € | +26.1% | 14,5 M € |
| Total assets | 12,5 M € | -41.8% | 21,5 M € | +7.4% | 20 M € |
| Cash | 3,2 M € | -68.5% | 10,1 M € | +197% | 3,4 M € |
| Debts | 978,2 k € | -46.4% | 1,8 M € | +13.3% | 1,6 M € |
| Other | |||||
| Workforce | 17,1 ETP | -12.3% | 19,5 ETP | +56.0% | 12,5 ETP |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20259 active · 6 ended
Active mandates
Ended mandates
Other companies at this address
Gaston Geenslaan 3 3001 Leuven| Company | CBE no. |
|---|---|
AUGUSTINE THERAPEUTICS● Active | 0722.705.230 |
COULTREON BIOPHARMA● Active | 1019.429.814 |
K5 Therapeutics● Active | 0757.718.072 |
Metaptys● Active | 0554.664.311 |
Montis Biosciences● Active | 0730.979.429 |
Perseus Biomics● Active | 0650.946.412 |
QUOMAK● Active | 0448.488.111 |
ReWind Therapeutics● Active | 0682.626.216 |
| 1040.853.946 | |
Tavira Therapeutics● Active | 0802.591.262 |
VEDRA THERAPEUTICS● Active | 1039.565.628 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Type of account | Full model | Full model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 30/06/2022 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 |
| Length of the financial year | 12 months | 12 months | 19 months |
| Filing date | 21/05/2026 | 23/07/2025 | 23/07/2025 |
| General meeting | 24/04/2026 | 25/04/2025 | 26/04/2024 |
| Currency of the financial year | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 5 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Full model | 31/12/2025 | 24/04/2026 | 21/05/2026 | Dutch | |
| Full model | 31/12/2024 | 25/04/2025 | 23/07/2025 | Dutch | |
| Abridged modelCorrection | 31/12/2023 | 26/04/2024 | 23/07/2025 | Dutch | |
| Abridged modelCorrection | 31/12/2023 | 26/04/2024 | 07/01/2025 | Dutch | |
| Abridged model | 31/12/2023 | 26/04/2024 | 26/06/2024 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 10 M€ and 25 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20259 active · 6 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates19/06/2025KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Other28/03/2025STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - BENAMING
- Mandates07/02/2025ONTSLAGEN - BENOEMINGEN
- Mandates03/10/2024MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
- Capital / shares31/07/2024KAPITAAL - AANDELEN
- Mandates24/11/2023KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates28/09/2022ONTSLAGEN - BENOEMINGEN
- Mandates18/08/2022STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-7,7 M €↑
- 2025Name changeAstriVax Therapeutics
- 2024Annual accounts 2024-8,2 M €↓
- 2023Annual accounts 2023-6,7 M €
- 2023Name changeAstriVax
- 04/07/2022IncorporationPublic limited company